Valuable insights from the epacadostat plus pembrolizumab clinical trials in solid cancers
Crossref DOI link: https://doi.org/10.1186/s12885-024-12432-1
Published Online: 2024-07-25
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mitchell, Tara C.
Text and Data Mining valid from 2024-07-25
Version of Record valid from 2024-07-25
Article History
First Online: 25 July 2024
Declarations
:
: Not applicable.
: Participation in scientific advisory boards for Merck, BMS, and Pfizer.